Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY22 Earnings Presentation
30 slides from Dr. Lal Pathlabs's earnings presentation, May 17, 2022
Slide 1: Exchange filing cover letter
May 17, 2022 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex Sandra (E) Dalal Street Mumbai - 400 051 Mumbai - 400 001 Subject: Corporate Presentation Q4 & FY22 Dear Sir/ Mada
Slide 2: Q4 FY22 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q4 FY22 Results Presentation May 17, 2022
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 4 Overview of Dr. Lal PathLabs 5 Key Performance Highlights 8 Financials 10 Financial Highlights 11 Operating Highlights 12 Management Commentary 13 Corporate Overview 14 Shareholding 28 Contact Us 29 DISCLAIMER: This presentation may contain ‘forward
Slide 5: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance India’s Leading & Trusted 20% 20% 120% Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend CAGR CAGR for FY 21-22 diagnostics 70+ years of experience chain in the in the field of diagnostics country with ~44% Rs. 344 crore (Net) PAN India ROCE Cash &
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Pan-India Unique and Established integrated successful brand coverage Varied Offerings operating model 277 clinical labs Well-positioned (including National Reference Lab at Catalogue of 491 test Scalable model in one of the Established consumer Delhi and Regional panels
Slide 7: FY22 Snapshot
FY22 Snapshot 32.0% INR 2087.4 Cr 34.5% INR 1691.3 Cr Revenues Non Covid Revenues Margin 34.7% 27.3 Mn 28.8% INR 600.4 Cr Patients Normalised EBITDA* 32.7% 66.0 Mn Margin 17.7% INR 369.1 Cr Samples Normalised PAT** * Normalised EBITDA excl. RSU, CSR **Normalised PAT excl. notional depreciation on co
Slide 8: Q4 FY22 Snapshot
Q4 FY22 Snapshot 12.7% INR 485.5 Cr 12.2% INR 419.7 Cr Revenues Non Covid Revenues Margin 13.2% 6.7 Mn 26.9% INR 130.7 Cr Patients Normalised EBITDA* 8.0% 16.3 Mn Margin 15.0% INR 72.9 Cr Samples Normalised PAT** * Normalised EBITDA excl. RSU, CSR **Normalised PAT excl. notional depreciation on cons
Slide 9: Key Performance Highlights
Key Performance Highlights Q4 FY22 & FY22: • Revenues up by 12.7% Y-o-Y to Rs. 485.5 crore in Q4 FY22. Revenue up by 32% to Rs 2087.4 crore in FY22 • Normalised EBITDA* is Rs. 130.7 crore, margin of 26.9% in Q4 FY22. In FY22, Normalised EBITDA* is Rs 600.4 crore, margin at 28.8%. • Normalised Profit
Slide 10: Non-COVID, COVID & Allied Revenue
Non-COVID, COVID & Allied Revenue Rs. Cr. Total 431 607 498 497 486 386 438 420 374 386 105 74 43 41 37 49 49 6 8 4 10 2 8 7 10 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Non COVID COVID* COVID Allied 1** COVID Allied 2*** *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dim
Slide 11: Financials
Financials Particulars (Rs. Cr.) Q4’22 Q4’21 Gr % FY'22 FY'21 Gr % Revenue 485.5 431.0 12.7% 2,087.4 1,581.3 32.0% Expenditure 364.5 308.9 1,526.7 1145.0 EBITDA 121.1 122.0 560.7 436.3 Stock based comp., CSR cost 9.6 7.5 39.7 26.3 Normalised EBITDA 130.7 129.5 0.9% 600.4 462.6 29.8% Normalised Margi
Slide 12: Financial Highlights
Financial Highlights All figures in Rs. Crore Revenue Normalised EBITDA* Normalised PBT** Normalised PAT** Total & Non Covid 493.8 369.1 2,087.4 600.4 394.4 296.5 1691.3 462.6 1,581.3 1257.1 +34.5% +32% Margin Margin Margin Margin Margin Margin 24.9% 23.7% 29.3% 28.8% 18.7% 17.7% FY21 FY22 FY21
Slide 13: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +77 +2,162 +4,173 277 4,731 9,247 10,599 200 216 231 3,705 6,426 6,995 2,569 3,095 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 No. of Patients (Mn) No. of Samples (Mn) +55% +58% 27.3 66.0 17.6 19.4 20.3 47.7 49
Slide 14: Management Commentary
Management Commentary Commenting on the results Commenting on the results Commenting on the results announcement, (Hony) Brig. Dr. Arvind announcement, Dr. Om Manchanda, announcement, Mr. Bharath Uppiliappan, Lal, Executive Chairman said: Managing Director said: Chief Executive Officer said: “India
Slide 15: Corporate Overview
Corporate Overview
Slide 16: Vision, Mission & Values
Vision, Mission & Values Be the most trusted Customer First healthcare partner, enabling healthier VISION lives Ethics & Integrity To be an undisputed market Quality leader by providing accessible, VALUES affordable, timely and quality healthcare, diagnostics, applying MISSION Accountability insight
Slide 17: Vibrant Outlook
Vibrant Outlook Target to grow ahead of the Evaluate best fit inorganic opportunities in South, and industry leverage expertise of recently acquired Suburban brand in West Higher contribution from bundling of tests – ‘Swasthfit’ Strongly develop Rest of India geographies, through Deeper Penetration
Slide 18: DLPL Strategy for future growth
DLPL Strategy for future growth 01 Strengthen Expansion in Offering Existing Operations 04 02 Expand management Geographic of hospital based and expansion 03 clinical laboratories Classification: Restricted 17
Slide 19: DLPL Strategy for future growth
DLPL Strategy for future growth • Boosting quality & reliability standards • Improving turnaround times for testing • Grow basic radiology practice Strengthen Existing • Online initiatives and data analytics Operations • Investment in branding • Improve breadth of diagnostic testing • Cutting edge t
Slide 20: Leveraging digital infrastructure to make life easier for patient
Leveraging digital infrastructure to make life easier for patient Digital Lab Logistics Automation • Self Registration Kiosk for patients • Field Executive Mobile App for Route • Integrated payment gateway for online payment Traceability & Field Executive Tracking • Self Report printing Kiosks for 2
Slide 21: Consistent investments in R&D
Consistent investments in R&D DSIR recognized In House R&D unit with an Sanger experienced team Sequencing, Single Variant of research scientists and doctors Sickle Cell Trio Leigh Syndrome Prenatal Mitochondrial Mutation Mutation Detection Successful Detection commercialization of tests Jawaharlal
Slide 22: Genevolve: The Genomics initiative
Genevolve: The Genomics initiative GENEVOLVE brings the dawn of a new era of Genomic testing! Genevolve: Genomics division focuses on Genetic testing Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre- natal/ Post-natal Tests are carried out using cutting edge
Slide 23: In-house adoption of Digital Histopathology
In-house adoption of Digital Histopathology Opportunities created by Digital Reporting of Digital Histopathology Breast cancer Panels using AI based • Enhanced access to second algorithms opinion, synchronous review of slides • Enhanced quality of reporting • Potential for insourcing services • Leve
Slide 24: Highest Quality Standards in the Industry
Highest Quality Standards in the Industry Best in the Industry CAP Proficiency Testing Score at 97.9% for National Reference Lab Consistently high EQAS Performance Testing Score at 98.6% for Satellite Labs NABL Accreditation granted to 18 Labs for processing Covid-19 samples 100+ Quality Digitally e
Slide 25: Best in class Logistics and Supply Chain management
Best in class Logistics and Supply Chain management Real time Automated Productivity Real time Real time Field Cash collection and route service sample Executive process with planning monitoring tracking tracking clients visibility Control tower Classification: Restricted 25
Slide 26: Enhanced Customer Experience in Home Collection
Enhanced Customer Experience in Home Collection Auto Routing engine to dynamically allocate Real time phlebo the booking to nearest visibility to the patient available phlebotomist Variable model Real time slot which grows confirmation with business to patient volume ECG at home Automated service an
Slide 27: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Group Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Compa
Slide 28: Key Awards & Recognition
Key Awards & Recognition CSR Award 2022 Business Standard Star GAPIO Excellence in Financial Express CFO CFO100 Roll of Dr. Om Manchanda ICICI Lombard & EY Entrepreneur SME of the year 2022 Diagnostics Award of the year 2022 Honour 2022 honoured and CNBC TV18 India of The Year 2019 2022 awarded as R
Slide 29: Shareholding as of 31st March, 2022
Shareholding as of 31st March, 2022 27.1% FIIs, FPIS, Foreign Company & NRIs 55.2% Promoter and Promoter 13.2% Group Others 4.5% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well Classification: Restricted 28
Slide 30: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests